<DOC>
	<DOCNO>NCT02167789</DOCNO>
	<brief_summary>This clinical investigation prospective , non-randomized , multi-center , pivotal trial.This trial perform order demonstrate sensivity diagnostic feature `` Physiological Diagnostic '' ( PhD ) .</brief_summary>
	<brief_title>Clinical Evaluation Physiological Diagnosis Function PARADYM CRT Device</brief_title>
	<detailed_description>The purpose study evaluate performance new sensor-based diagnostic feature , physiological Diagnostic ( PhD ) implement PARADYM CRT Cardiac Resynchronization System defibrillation capabalities ( PARADYM CRT System , model 8770 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient eligible implantation CRTD device accord current available guideline cardiac resynchronization therapy Severe HF ( NYHA Class III IV ) time enrollment At least one HFrelated event ( define primary objective ) within last 6 month enrolment Subject continue heart failure symptom despite receive optimal medical therapy consistent current practice guideline pharmacological management heart failure Scheduled implant PARADYM 8770 Signed date informed consent Any contraindication standard cardiac pace Any contraindication ICD therapy Abdominal implantation side Hypertrophic obstructive cardiomyopathy Acute myocarditis Unstable coronary symptom ( unstable angina myocardial infarction ) within last month Recent ( within last month ) plan cardiac revascularization coronary angioplasty Correctable valvular disease primary cause heart failure Mechanical tricuspid valve Receiving continuous intravenous infusion positive inotropic therapy intermittent therapy ( intravenous infusion ) twice per week Heart transplant recipient Renal insufficiency require dialysis Already include another clinical study Life expectancy le 12 month Inability understand purpose study refusal cooperate Inability refusal provide inform consent , part inform consent , Health Insurance Portability Accountability Act ( HIPAA ) authorization Unavailability schedule followup implanting center Known sensitivity 1 mg dexamethasone sodium phosphate ( DSP ) Under guardianship Age le 18 year Pregnancy ( Women childbearing potential negative pregnancy test prior enrollment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HF , diagnosis</keyword>
</DOC>